95°F
weather icon Cloudy

Sandoval signs bill to increase insulin price transparency

Updated June 15, 2017 - 7:18 pm

Gov. Brian Sandoval signed off on a bill Thursday that requires pharmaceutical companies to release insulin prices, weeks after vetoing a similar bill that he said wasn’t strong enough.

During a Thursday morning public signing ceremony at the North Las Vegas Culinary Health Center — one of three public signings the governor held during a day of ceremonies throughout the Las Vegas Valley — Sandoval mentioned his grandfather’s struggle with diabetes as a motivator to sign Senate Bill 539, which targets insulin prices.

“This was my mom’s dad, and he’s somebody that I saw suffer because of that,” Sandoval said. “I typically don’t talk about personal things, but it kind of welled up in me as I was here today. Statewide, it’s going to make a difference, I believe, with regard to transparency in drugs for those suffering from diabetes and transparency for insulin.”

The governor was joined by several officials, including state Sen. Yvanna Cancela, D-Las Vegas, former U.S. Sen. Harry Reid, Clark County Commissioner Lawrence Weekly, and a throng of culinary union workers and medical professionals who celebrated the unveiling of the North Las Vegas Culinary Health Center prior to the bill signing.

Cancela proposed the bill Sandoval vetoed before joining forces with Sen. Michael Roberson, R-Henderson, to push SB539.

The bill is the country’s strictest drug-price disclosure rule, though insulin prices continue to rise — per-patient spending on the drug tripled between 2002 and 2013, according to a Journal of the American Medical Association article.

The law mandates pharmaceutical companies disclose how they set insulin prices, manufacturing costs, research investments and projects annually. Supporters of SB539 say it will help lower drug costs, but market experts have said the law alone isn’t enough.

Still, Sandoval said he thinks the law is a positive first step toward holding drug companies accountable.

“Let’s see how this works,” he said. “If changes need to be made, those can be approached or pursued in the 2019 legislative session, but you have to start somewhere.”

Contact Jessie Bekker at jbekker@reviewjournal.com or 702-380-4563. Follow @jessiebekks on Twitter.

THE LATEST
Lawsuit challenges Nevada’s new diabetes drug disclosure law

Two pharmaceutical groups have filed a lawsuit in federal court challenging the constitutionality of a bill passed by the 2017 Nevada Legislature requiring disclosure of the pricing of diabetes drugs.

Nevada Legislature approves final payment for ESA software

The final action on Nevada’s controversial private school choice program came Thursday when the Legislature’s Interim Finance Committee approved $105,000 to pay off the remaining costs incurred by a vendor who was working on the development of software to implement the program.

 
Recall targets a third Nevada senator

A third recall petition against a female Nevada state senator was filed Wednesday.

Federal government approves Nevada’s education plan

Nevada is among four states to get U.S. Education Department approval of its plan as required under a new federal education law, the Every Student Succeeds Act, or ESSA.